Nurix Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDNurix Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 93), indicating clear outperformance against the broad market. Earnings contraction of 18% provides fundamental context to the price action. However, with RSI at 82, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $19.80 | +23.26% | ABOVE |
| 50 SMA | $17.83 | +36.86% | ABOVE |
| 100 SMA | $16.78 | +45.38% | ABOVE |
| 150 SMA | $17.29 | +41.11% | ABOVE |
| 200 SMA | $15.81 | +54.34% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NRIX in an uptrend right now?
NRIX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is NRIX overbought or oversold?
NRIX's RSI (14) is 82. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is NRIX outperforming the market?
NRIX has a Relative Strength (RS) Rating of 93 out of 99. Yes, NRIX is a market leader, outperforming 93% of all stocks over the past 12 months.
Where is NRIX in its 52-week range?
NRIX is trading at $24.40, which is 98% of its 52-week high ($24.88) and 97% above its 52-week low ($8.20).
How volatile is NRIX?
NRIX has a Beta of 1.56 and 52-week volatility of 63%. It's more volatile than the S&P 500 - expect bigger swings.